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Abstract 
Aryl hydrocarbon receptor nuclear translocator (ARNT) 2 is a transcriptional factor 
related to adaptive responses against cellular stress from a xenobiotic substance. Recent 
evidence indicates ARNT is involved in carcinogenesis and cancer progression; however, 
little is known about the relevance of ARNT2 in the behavior of oral squamous cell 
carcinoma (OSCC). In the current study, we evaluated the ARNT2 mRNA and protein 
expression levels in OSCC in vitro and in vivo and the clinical relationship between 
ARNT2 expression levels in primary OSCCs and their clinicopathologic status by 
quantitative reverse transcriptase-polymerase chain reaction, immunoblotting, and 
immunohistochemistry. Using ARNT2 overexpression models, we performed functional 
analyses to investigate the critical roles of ARNT2 in OSCC. ARNT2 mRNA and protein 
were down-regulated significantly (P < 0.05 for both comparisons) in nine OSCC-derived 
cells and primary OSCC (n=100 patients) compared with normal counterparts. In addition 
to the data from exogenous experiments that ARNT2-overexpressed cells showed 
decreased cellular proliferation, ARNT2-positive OSCC cases were correlated 
significantly (P < 0.05) with tumoral size. Since von Hippel-Lindau tumor suppressor, E3 
ubiquitin protein ligase, a negative regulator of hypoxia-inducible factor (HIF1)-α, is a 
downstream molecule of ARNT2, we speculated that HIF1-α and its downstream 
molecules would have key functions in cellular growth. Consistent with our hypothesis, 
overexpressed ARNT2 cells showed down-regulation of HIF1-α, which causes 
hypofunctioning of glucose transporter 1, leading to decreased cellular growth. Our results 
proposed for the first time that the ARNT2 level is an indicator of cellular proliferation in 
OSCCs. Therefore, ARNT2 may be a potential therapeutic target against progression of 
OSCCs. 
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Introduction 
The transcription factors aryl hydrocarbon receptor nuclear translocator (ARNT) and 
ARNT2 have important roles in adaptive responses to generalized and cellular stress (1-5). 
The amino acid sequence of ARNT2 is more than 90% identical to that of ARNT (6, 7). 
Whereas ARNT is expressed ubiquitously both during fetal development and throughout 
adulthood, ARNT2 is expressed predominately in the central nervous system and 
developing kidney (8-12). ARNT2 acts as a common obligate partner for several other 
members of the family, including aryl hydrocarbon receptor and single-minded 1, a 
transcription factor (13-15). ARNT2 knockout mice and zebrafish have severe 
developmental defects and die shortly after birth (16-19). 
ARNT2 mRNA expression levels are correlated positively with breast cancer 
prognosis, and the presence of ARNT2 was associated significantly with smaller tumoral 
sizes and the 5-year survival rate after breast cancer diagnosis (12). A high intratumoral 
ARNT2 level was well correlated with longer overall survival and lower tumoral 
recurrence of hepatocellular carcinoma after resection (20). Although many of the 
functions of ARNT2 are unknown, those perspective findings indicate a possible role of 
ARNT2 in oral squamous cell carcinoma (OSCC) development, treatment, and outcome. 
In addition to our previous data that indicated that ARNT2 is a significantly down-
regulated gene in OSCC (21), we report here that lower ARNT2 expression is associated 
with tumoral size in OSCCs. Therefore, we propose that ARNT2 may be a key regulator 
of tumoral progression in OSCCs. 
  
  
Materials and Methods 
Ethics statement 
The Ethics Committee of the Graduate School of Medicine, Chiba University, 
approved the study protocol (approval number, 236). The study was performed according 
to the tenets of the Declaration of Helsinki. All patients provided written informed consent 
before participating in this research. 
 
OSCC-derived cell lines and tissue specimens 
Human OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, KOSC-2, Ho-1-u-1, Ho-1-N-1, 
Sa3, Ca9-22, and SAS) were obtained from the Human Science Research Resources Bank 
(Osaka, Japan) or the RIKEN BioResource Center (Ibaraki, Japan) through the National 
Bio-Resource Project of the Ministry of Education, Culture, Sports, Science and 
Technology (MEXT) (Tokyo, Japan). Short tandem repeat proﬁles conﬁrmed the cellular 
identity. Primary cultured human normal oral keratinocytes (HNOKs) were obtained from 
three healthy donors and served as a normal control (22-26). All cells were grown in 
Dulbecco’s modified Eagle medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with 10% fetal bovine serum (FBS) (Sigma) and 50 units/ml penicillin and 
streptomycin (Sigma).  
One hundred primary OSCC samples and patient-matched normal epithelial 
specimens were obtained during surgeries performed at Chiba University Hospital. The 
resected tissues were fixed in 20% buffered formaldehyde solution for pathologic 
diagnosis and immunohistochemistry (IHC). Histopathologic diagnosis of each OSCC 
sample was performed according to the World Health Organization criteria by the 
Department of Pathology of Chiba University Hospital. Clinicopathologic staging was 
  
determined by the TNM classification of the International Union against Cancer (27). All 
patients had OSCC that was histologically confirmed, and tumoral samples were checked 
to ensure that tumoral tissue was present in more than 80% of specimens. 
 
Preparation of cDNA and protein 
Total RNA was isolated using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. cDNA was generated from 5 µg total RNA 
using Ready-To-Go You-Prime First-Strand Beads (GE Healthcare, Buckinghamshire, 
UK) and oligo (dT) primer (Hokkaido System Science, Sapporo, Japan) according to the 
manufacturer’s instructions.  
For protein extraction, the cells were washed twice with cold phosphate buffered 
saline (PBS) and centrifuged briefly. The cellular pellets were incubated at 4°C for 30 
minutes in a lysis buffer (7 M urea, 2 M thiourea, 4% w/v CHAPS, and 10 mM Tris pH 
7.4) with a proteinase inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). The 
protein concentration was measured using the BCA Protein Assay Kit (Thermo, Rockford, 
IL, USA). 
 
mRNA expression analysis 
Real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) 
was performed using the LightCycler 480 apparatus (Roche Diagnostics). Primers and 
universal probes were designed using the Universal Probe Library (Roche Diagnostics), 
which speciﬁes the most suitable set. The primer sequences used for qRT-PCR were: 
ARNT2, forward, 5’- TGAGGGGTACAGGGAACAAG -3’; reverse, 5’- 
GAGATTTGGGACATGTTCTGG -3’; and universal probe #35; GAPDH, forward, 5’- 
  
AGCCACATCGCTCAGACAC-3’; reverse, 5’-GCCCAATACGACCAAATCC-3’; and 
universal probe #60; von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase 
(VHL), forward, 5’-TGAGCTGATATCGCACCATT-3’; reverse, 5’-
CTGGAGTGTCTCATTCACTTCACT-3’; and universal probe #19; hypoxia inducible 
factor 1, alpha subunit (HIF-1α), forward, 5’- TTTTTCAAGCAGTAGGAATTGGA-3’; 
reverse, 5’-GTGATGTAGTAGCTGCATGATCG-3’; and universal probe #66; and solute 
carrier family 2 (facilitated glucose transporter), member 1 (GLUT-1), forward, 5’- 
GGTTGTGCCATACTCATGACC-3’; reverse, 5’-CAGATAGGACATCCAGGGTAGC -
3’;nand universal probe #67. 
The transcript amounts for ARNT2, VHL, HIF-1α, and GLUT-1 were estimated from 
the respective standard curves and normalized to the GAPDH transcript amount 
determined in corresponding samples. All samples were analyzed in triplicate and three 
independent preparations of RNA were analyzed from each cell line. 
 
Immunoblot analysis 
 Protein extracts (20 µg) were separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis in 10% gel, transferred to nitrocellulose membranes, and blocked for 1 
hour at room temperature in Blocking One (Nacalai Tesque, Tokyo, Japan). The 
membranes were incubated with rabbit anti-ARNT2 polyclonal antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), mouse anti-GAPDH monoclonal antibody (Santa 
Cruz Biotechnology), mouse anti-VHL monoclonal antibody (Cell Signaling Technology, 
Danvers, MA, USA), rabbit anti-HIF-1α polyclonal antibody (Cell Signaling Technology), 
and mouse anti-GLUT-1 monoclonal antibody (Arigo Biotechnology, Hsinchu City, 
Taiwan, China) overnight at 4°C. The membranes were washed with 0.1% Tween-20 in 
  
Tris-buffered saline and incubated with secondary antibody coupled to horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse IgG (Promega, Madison, WI, USA) for 1 
hour at room temperature. Finally, bands were detected using SuperSignal West Pico 
Chemiluminescent substrate (Thermo), and immunoblotting was visualized by exposing 
the membranes to the BioRad ChemiDoc™ XRS System (BioRad, Tokyo, Japan). The 
signal intensities were quantitated using Image Lab software (BioRad). Densitometric 
ARNT2, VHL, HIF-1α, and GLUT-1 protein data were normalized to GAPDH protein 
levels. 
 
IHC 
IHC was performed on 4-µm sections of paraffin-embedded specimens using rabbit 
anti-ARNT2 polyclonal antibody (Santa Cruz Biotechnology). Briefly, after 
deparaffinization and hydration, the endogenous peroxidase activity was quenched by a 
30-minute incubation in a mixture of 0.3% hydrogen peroxide solution in 100% methanol; 
the sections were blocked for 2 hours at room temperature with 1.5% blocking serum 
(Santa Cruz Biotechnology) in PBS before reacting with anti-ARNT2 antibody at 4°C in a 
moist chamber overnight. Upon incubation with the primary antibody, the specimens were 
washed three times in PBS and treated with Envision reagent (DAKO, Carpinteria, CA, 
USA) followed by color development in 3,3’-diaminobenzidine tetrahydrochloride 
(DAKO). The slides then were slightly counterstained with hematoxylin, dehydrated with 
ethanol, cleaned with xylene, and mounted. Nonspecific binding of an antibody to proteins 
other than the antigen sometimes occurred. As a negative control, triplicate sections were 
immunostained without exposure to primary antibodies, which confirmed the staining 
specificity. To quantify the status of ARNT2 protein expression in those components, we 
  
used the IHC scoring systems described previously (28-32). In summary, the mean 
percentages of positive tumoral cells were determined in at least three random fields at 
400× magnification in each section. The intensity of the ARNT2 immunoreaction was 
scored as follows: 0+, none; 1+, weak; 2+, moderate; and 3+, intense. The cellular number 
and the staining intensity were multiplied to produce an ARNT2 IHC score. To determine 
the cutoff points of ARNT2 IHC scores, we analyzed the IHC scores of 100 patients using 
the receiver operating characteristic (ROC) curve and the Youden index. Cases with a 
score above 107.0 were defined as ARNT2-positive. Two independent pathologists from 
Chiba University Hospital, neither of whom had knowledge of the patients’ clinical status, 
made these judgments. 
 
Plasmid construction and transfection of ARNT2 overexpression vector 
To construct the ARNT2 overexpression vector, the Gateway® LR clonase enzyme 
mix kit (Invitrogen) was used for the LR recombination reaction, including 100 ng of 
entry clone plasmid DNA (CUSABIO, Wuhan, China), 100 ng of destination vector 
pcDNA-DEST47 (Invitrogen), 2 μl of 5 × LR clonase reaction buffer, and 2 μg of LR 
clonase enzyme. The mixture was brought to a final volume of 10 μl with TE buffer (pH 
8.0) and incubated at room temperature for 1 hour.  
The HSC-3 and KOSC-2 cell lines were transfected with the ARNT2 overexpression 
vector (oeARNT2) or control vector (Mock) (Invitrogen) using Lipofectamine 3000 
reagents (Invitrogen). After transfection, the stable transfectants were isolated by the 
culture medium containing 300 μg/mL G418 solution (Invitrogen). Two to three weeks 
after selection, viable colonies were transferred to new dishes. The oeARNT2 and Mock 
cells were used for further experiments. 
  
 
Proliferation assay 
The transfectants were seeded in six-well plates at a density of 1 × 104 viable cells 
per well. The cells were cultured for 168 hours and counted every 24 hours. At the 
indicated time points, the cells were trypsinized and counted using a hemocytometer in 
triplicate samples. 
 
Immunofluorescence 
The transfectants were plated on chamber slides (Becton-Dickinson Falcon, Franklin 
Lakes, NJ, USA) at 50% confluency, washed with ice-cold PBS, fixed with 4% 
paraformaldehyde-PBS for 20 min, and then permeabilized in PBS containing 0.2% Triton 
X-100 as described previously (24). Fixed cells were incubated with a blocking solution 
containing 0.5% bovine serum albumin for 1 hour at room temperature and incubated with 
primary antibodies overnight at 4°C. We used the following primary antibodies: rabbit 
anti-ARNT2 polyclonal antibody (Santa Cruz Biotechnology) and mouse anti-GLUT-1 
monoclonal antibody (Arigo Biolaboratories). After washing with PBS, the cells were 
incubated with secondary antibodies for 1 hour at room temperature. The secondary 
antibodies were fluorescein isothiocyanate-conjugated anti-rabbit IgG antibody (Vector 
Laboratories, Burlingame, CA, USA) or Texas Red-conjugated anti-mouse IgG antibody 
(Vector Laboratories) incubated for 1 hour at room temperature in the dark. Finally, the 
sections were washed three times with PBS and mounted using Mounting Medium with 
DAPI (Vector Laboratories). The immunofluorescence was performed by confocal 
microscopy and analyzed using FluoView Software (Olympus Optical, Tokyo, Japan). 
 
  
Glucose cellular uptake assay 
The glucose uptake value was determined by the levels of intracellular 2-
deoxyglucose 6-phosphate (2-DG) using the Glucose Cellular Uptake Measurement Kit 
(Cosmo Bio, Tokyo, Japan). The transfectants were seeded in six-well plates at a density 
of 1 × 104 viable cells per well and then cultured in DMEM without FBS for 6 hours. Each 
well was washed three times with Krebs-Ringer Phosphate HEPES (KRPH) buffer and the 
cells were cultured in KRPH buffer containing 1 mM 2-DG for 1 hour. The wells were 
washed three times with PBS containing 200 μM phloretin to quench the glucose uptake. 
The cells were sonicated and centrifuged at 15,000 x g for 20 minutes. The supernatant 
was mixed with reaction buffer and incubated at 80 °C for 15 minutes. The mixture was 
added to a 96-well plate and incubated for 2 hours at 37 °C. The fluorescence intensity 
was measured at an excitation wavelength of 540 nm and an emission wavelength of 590 
nm using a plate reader. 
 
Statistical analysis 
In comparisons of the ARNT2 expression levels, statistical significance was 
evaluated using the Mann-Whitney U test. The relationships between the ARNT2 IHC 
scores and clinicopathological profiles were evaluated by the Mann-Whitney U test, χ2 
test, and Fisher’s exact test. P < 0.05 was considered significant. The data are expressed as 
the mean ± standard error of the mean. 
  
  
Results 
Evaluation of ARNT2 expression in OSCC-derived cell lines 
To investigate the expression status of ARNT2, we performed qRT-PCR and 
immunoblot analyses using nine OSCC-derived cell lines (HSC-2, HSC-3, HSC-4, KOSC-
2, Ho-1-u-1, Ho-1-N-1, Sa3, Ca9-22, and SAS) and HNOKs. ARNT2 mRNA was down-
regulated significantly (P < 0.05) in all OSCC-derived cell lines compared with the 
HNOKs (Fig. 1A). Fig. 1B shows representative results of immunoblot analysis. The 
ARNT2 protein expression decreased significantly (P < 0.05) in all OSCC-derived cell 
lines compared with the HNOKs.  
 
Evaluation of ARNT2 expression in primary OSCCs 
We analyzed the ARNT2 protein expression in primary OSCCs from 100 patients 
using the IHC scoring system (33-39). The ARNT2 IHC scores in adjacent normal oral 
tissues and OSCCs ranged from 40 to 180 (median, 135) and 10 to 157 (median, 75). The 
IHC scores in the primary OSCCs were significantly (P < 0.05) lower than in normal oral 
tissues (Fig. 2A). Fig. 2B and C, respectively, show representative IHC results for ARNT2 
protein in adjacent normal oral tissue and primary OSCCs. Strong ARNT2 
immunoreactivity was detected in the nuclei of normal tissues, whereas the OSCC tissues 
showed almost negative immunostaining. To determine an optimal cutoff point of the 
identified IHC scores, we used ROC curve analysis and the Youden index. The ROC 
curve analysis (area under the curve, 0.896; 95% confidence interval [CI], 0.8201-
0.9438; P < 0.05) and Youden index (sensitivity, 85.0%; specificity, 83.3%; P < 0.05) 
showed that the cutoff value was 107 (Fig. 2D, E). Table 1 shows the correlations 
between the clinicopathological characteristics of the patients with OSCC and the status 
  
of ARNT2 protein expression. Among the clinical parameters, the ARNT2 expression 
level was significantly (P < 0.05) related to the primary tumoral size of the OSCCs.  
 
Establishment of ARNT2 overexpressed cells 
Since frequent down-regulation of ARNT2 was observed in the OSCC-derived cells 
(Fig. 1), the OSCC-derived cells (HSC-3 and KOSC-2) were transfected with ARNT2 
overexpression vector (oeARNT2) and control vector (Mock). To confirm the efficiency 
of the transfections, we performed qRT-PCR and immunoblot analyses (Fig. 3A, B). The 
ARNT2 mRNA expression level in the oeARNT2 cells was significantly (P < 0.05) greater 
than in the Mock cells (Fig. 3A). The ARNT2 protein level in the oeARNT2 cells also 
increased compared with the Mock cells (Fig. 3B). 
 
Cellular proliferation of ARNT2 overexpressed cells 
To evaluate the effect of ARNT2 overexpression on cellular growth, we performed a 
cellular proliferation assay. We found a significant (P < 0.05) decrease in cellular growth 
in the oeARNT2 cells compared with the Mock cells (Fig. 4A). Images were obtained 
after 12 and 120 hours using a Leica LCD microscope (Leica Microsystems, Wetzlar, 
Germany) (original magnification, x200) (Fig. 4B). 
 
Evaluation of VHL, HIF1-α, and GLUT-1 expression levels in ARNT2 overexpressed 
cells 
Since VHL a negative regulator of HIF1-α, is a molecule downstream from ARNT2 
(14), we investigated the VHL and HIF1-α expression levels in ARNT2-overexpressed 
cells. The VHL mRNA and protein expression levels in the oeARNT2 cells were 
  
significantly (P < 0.05) greater than in Mock cells (Fig. 5A, B). In contrast, the HIF1-α 
mRNA and protein expression levels in the oeARNT2 cells were significantly (P < 0.05) 
lower than in the Mock cells (Fig. 5C, D). The GLUT-1, a HIF1-α related molecule, 
mRNA and protein expression levels in the oeARNT2 cells measured by qRT-PCR, 
immunoassay, and glucose cellular uptake analyses were significantly (P < 0.05) lower 
than in Mock cells (Fig. 5E, F). The immunofluorescence data showed strong 
immunoreactivity of ARNT2 and weak immunoreactivity of GLUT-1 in the oeARNT2 
cells, whereas the Mock cells showed weak immunoreactivity of ARNT2 and strong 
immunoreactivity of GLUT-1 (Fig. 5G). The glucose cellular uptake assay showed that 
ARNT2 overexpression resulted in significantly (P < 0.05) decreased levels of glucose 
uptake compared with the Mock cells (Fig. 5H, I). 
  
  
Discussion 
The current study found that ARNT2 was down-regulated frequently in OSCCs and 
was correlated with tumoral progression. Consistent with these clinical findings (Fig. 2), 
in vitro experiments showed that ARNT2 overexpression significantly inhibits cellular 
proliferation (Fig. 4). 
ARNT2 expression is a prognostic marker and a potential therapeutic target in breast 
and hepatocellular cancers (12, 20). High expression of ARNT2 is associated with 
extended survival rates from the time of diagnosis in both cancers (12, 20), suggesting that 
ARNT2 plays important roles in cancer development and progression. However, similar to 
our current study, exogenous overexpressed ARNT2 in non-small cell lung cancer cells 
significantly decreased the capacity for proliferation and increased cell apoptosis (40). 
Therefore, ARNT2 plays pivotal roles in development and progression of several types of 
cancers. 
We also found a new pathway downstream of ARNT2 in OSCCs. Briefly, 
overexpressed ARNT2 positively regulated VHL, a tumor suppressor gene, which 
ubiquitinates HIF1-α for degradation by the proteasome (41), leading to down-regulation 
of GLUT-1. Without VHL, HIF-1α translocates to the nucleus to activate the expression of 
its target genes, such as GLUT-1 (41). HIF-1α increases the rate of glucose uptake through 
the transcriptional activation of GLUT-1 (42, 43). Elevated expression levels of either 
HIF1-α or GLUT-1 has been detected in many different cancers, including head and neck 
tumors (44-47). GLUT-1 expression is undetectable primarily in normal epithelial tissues 
and benign epithelial tumors. GLUT-1 protein expression is associated with a poor 
prognosis in a wide range of solid tumors (48-52). Actually, in the current study, we found 
that overexpressed ARNT2 cells had significantly (P < 0.05) decreased cellular growth 
  
and levels of glucose uptake compared with Mock cells (Fig. 5). 
In conclusion, ARNT2 is frequently down-regulated in OSCCs and plays an 
important role in OSCC progression through the VHL-HIF1-α-GLUT-1 axis. Therefore, 
ARNT2 expression is likely to be a biomarker of proliferation, a prognostic indicator, and 
a potential therapeutic target for OSCC. 
 
  
  
Abbreviations 
ARNT2: aryl hydrocarbon receptor nuclear translocator 2; OSCC: oral squamous cell 
carcinoma; qRT-PCR: quantitative reverse transcriptase-polymerase chain reaction; IHC: 
immunohistochemistry; HNOKs: human normal oral keratinocytes; oeARNT2: 
overexpression of ARNT2.  
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Legends 
Figure 1. Evaluation of ARNT2 expression in OSCC-derived cell lines. (A) 
Quantification of ARNT2 mRNA expression in OSCC-derived cell lines by qRT-PCR 
analysis. Significant (*P < 0.05, Mann-Whitney U-test) down-regulation of ARNT2 
mRNA is seen in nine OSCC-derived cell lines compared with HNOKs. Data are 
expressed as the means ± standard errors of the mean of triplicate results. (B) Immunoblot 
analysis of ARNT2 protein in OSCC-derived cell lines and HNOKs. ARNT2 protein 
expression is down-regulated in OSCC-derived cell lines compared with that in HNOKs. 
Densitometric ARNT2 protein data are normalized to GAPDH protein levels. The values 
are expressed as a percentage of HNOKs. 
 
Figure 2. Evaluation of ARNT2 expression in primary OSCCs. (A) The ARNT2 IHC 
scores in adjacent normal oral tissues and OSCCs range from 40 to 180 (median, 135) and 
10 to 157 (median, 75), respectively. The IHC scores in primary OSCCs are significantly 
(*P < 0.05) lower than in normal oral tissues. Representative IHC results for ARNT2 
protein in (B) normal oral tissue and primary (C) OSCC. Strong ARNT2 
immunoreactivity is seen in normal oral tissues, whereas the OSCCs show almost negative 
immunostaining. Original magnification, x 100. (D) ROC curve analysis shows the 
optimal cutoff value is 107.5 (area under the curve, 0.896; 95% CI, 0.8201-0.9438; *P < 
0.05). (E) The Youden index (sensitivity, 85.0%; specificity, 83.3%; *P < 0.05) also 
shows that the optimal cutoff value is 107.5. AUC, area under the curve. 
 
Figure 3. Establishment of ARNT2 overexpressed cells. Significant (*P < 0.05, Mann-
Whitney U test) up-regulation of (A) ARNT2 mRNA and (B) protein are observed in 
  
oeARNT2 cells compared with that in Mock cells using qRT-PCR and immunoblot 
analyses. Densitometric ARNT2 protein data are normalized to GAPDH protein levels. 
The values are expressed as a percentage of the Mock cells.  
 
Figure 4. Cellular proliferation of ARNT2 overexpressed cells. (A) To determine the 
effect of ARNT2 overexpression on cellular proliferation, oeARNT2 and Mock cells are 
seeded in six-well plates at a density of 1 × 104 viable cells per well. Both transfectants are 
cultured for 168 hours and counted every 24 hours. The oeARNT2 cells have significantly 
(P < 0.05) decreased cellular growth compared with the Mock cells. (B) Images are 
obtained after 12 and 120 hours using a Leica LCD microscope (original magnification, 
x200) and are representative of three independent experiments. The results are expressed 
as the means ± standard errors of the mean of values from three assays. h, hours. 
 
Figure 5. Evaluation of VHL, HIF1-α, and GLUT-1 expression levels in ARNT2 
overexpressed cells. (A) Expression of VHL mRNA in oeARNT2 and Mock cells. The 
VHL mRNA expression level in the oeARNT2 cells is significantly (*P < 0.05, Mann-
Whitney U test) higher than in the Mock cells. (B) Immunoblot analysis shows that the 
VHL protein levels in the oeARNT2 cells are increased markedly compared with the 
Mock cells. (C) Expression of HIF1-α mRNA in the oeARNT2 and Mock cells. The 
HIF1-α mRNA expression level in the oeARNT2 cells is significantly (*P < 0.05, Mann-
Whitney U test) lower than in the Mock cells. (D) Immunoblot analysis shows that the 
HIF1-α protein levels in the oeARNT2 cells are decreased markedly compared with the 
Mock cells. (E) The expression levels of GLUT-1 mRNA in the oeARNT2 and Mock 
cells. The GLUT-1 mRNA expression level in the oeARNT2 cells is significantly (*P < 
  
0.05, Mann-Whitney U test) lower than in the Mock cells. (F) Immunoblot analysis shows 
that the GLUT-1 protein levels in the oeARNT2 cells are also decreased markedly 
compared with the Mock cells. (B, D, F) Densitometric protein data are normalized to the 
GAPDH protein levels. The values are expressed as a percentage of the Mock cells. (G) 
Strong immunoreactivity of ARNT2 and weak immunoreactivity of GLUT-1 are seen in 
the oeARNT2 cells, whereas strong immunoreactivity of GLUT-1 and weak 
immunoreactivity of ARNT2 are seen in the Mock cells (red, ARNT2; green, GLUT-1; 
blue, DNA). ARNT2 is localized in the nucleus and cytosol of the oeARNT2 cells. GLUT-
1 is localized in the cell membrane. (H, I) A glucose uptake assay shows that ARNT2 
overexpression results in significantly (P < 0.05) decreased levels of glucose uptake 
compared with the Mock cells. The values are expressed as a percentage of the Mock 
cells. 
  
  
Table 1. Correlation between ARNT2 expression and clinical classification in OSCCs.  
Clinical classification  Results of immunostaining  
 Total ARNT2 negative ARNT2 positive P value 
Age at surgery (years)     
  <60 26 21 5 
0.3618   ≧60, <70 25 21 4 
  ≧70 49 34 15 
Gender     
  Male 62 45 17 
0.3446 
  Female 38 31 7 
T-primary tumor     
  T1 8 6 2 
0.02087＊ 
  T2 60 51 9 
  T3 16 10 6 
  T4 16 9 7 
N-regional lymph node    
  Negative 63 51 12 
0.1506 
  Positive 37 25 12 
Stage     
  I 6 4 2 
0.1049 
  II 42 36 6 
  III 17 13 4 
  IV 35 23 12 
Vascular invasion     
Negative 74 59 15 
0.439 
Positive 26 17 9 
Histopathologic type     
  Well differentiated 62 48 14 
0.807   Moderately differentiated 32 23 9 
  Poorly differentiated 6 5 1 
Tumoral site     
Tongue 51 40 11 
0.6045 
Gingiva 29 21 8 
Buccal mucosa 10 8 2 
Soft palate 3 2 1 
Oral floor 7 5 2 
＊P<0.05 is significant. 
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